Last reviewed · How we verify
IV Iron
IV Iron, marketed by Pfizer, holds a significant position in the treatment of iron deficiency anemia. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity that supports its competitive stance. The primary risk to Pfizer's IV Iron is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | IV Iron |
|---|---|
| Also known as | Venofer, iron sucrose, iron isomaltoside (Monofer, Monoferric) ferric gluconate (FG) iron sucrose (IS), Fe placebo, Ferinject |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging (PHASE1)
- Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation (NA)
- Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study (PHASE3)
- Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure (NA)
- Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients (PHASE3)
- T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Iron CI brief — competitive landscape report
- IV Iron updates RSS · CI watch RSS
- Pfizer portfolio CI